No Benefit for Idarucizumab.
作者信息
Pommer Peter
出版信息
Dtsch Arztebl Int. 2016 Aug 8;113(31-32):541. doi: 10.3238/arztebl.2016.0541a.
Abstract
摘要
相似文献
1
No Benefit for Idarucizumab.
Dtsch Arztebl Int. 2016 Aug 8;113(31-32):541. doi: 10.3238/arztebl.2016.0541a.
2
Idarucizumab for dabigatran overdose in a child.
Br J Haematol. 2018 Feb;180(3):457-459. doi: 10.1111/bjh.14371. Epub 2016 Oct 13.
3
Reversal of dabigatran anticoagulation ex vivo: Porcine study comparing prothrombin complex concentrates and idarucizumab.
Thromb Haemost. 2015 Apr;113(4):728-40. doi: 10.1160/TH14-08-0712. Epub 2015 Jan 8.
4
Idarucizumab, a Specific Dabigatran Reversal Agent, Reduces Blood Loss in a Porcine Model of Trauma With Dabigatran Anticoagulation.
J Am Coll Cardiol. 2015 Sep 29;66(13):1518-9. doi: 10.1016/j.jacc.2015.07.051.
5
Comment on: "Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study".
Clin Pharmacokinet. 2017 Feb;56(2):207-208. doi: 10.1007/s40262-016-0481-5.
6
Idarucizumab (Praxbind) for Dabigatran (Pradaxa) Anticoagulant Reversal.
Am Fam Physician. 2017 Jun 15;95(12):798-800.
7
Idarucizumab for Reversal of Dabigatran Prior to Acute Surgery: A Schematic Approach Based on a Case Report.
Basic Clin Pharmacol Toxicol. 2017 Apr;120(4):407-410. doi: 10.1111/bcpt.12696. Epub 2016 Dec 16.
8
Reversing the anticoagulation effects of dabigatran.
Hosp Pract (1995). 2017 Apr;45(2):29-38. doi: 10.1080/21548331.2017.1298389. Epub 2017 Mar 24.
9
Reversal of Dabigatran with Idarucizumab.
Expert Rev Cardiovasc Ther. 2016 Aug;14(8):889-93. doi: 10.1080/14779072.2016.1203253. Epub 2016 Jun 30.
10
A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran.
Thromb Haemost. 2015 May;113(5):943-51. doi: 10.1160/TH14-12-1080. Epub 2015 Mar 19.
本文引用的文献
1
The Periprocedural Management of Anticoagulation and Platelet Aggregation Inhibitors in Endoscopic Interventions.
Dtsch Arztebl Int. 2016 Feb 26;113(8):129-35. doi: 10.3238/arztebl.2016.0129.
2
Idarucizumab for Dabigatran Reversal.
N Engl J Med. 2015 Aug 6;373(6):511-20. doi: 10.1056/NEJMoa1502000. Epub 2015 Jun 22.
Zotero 插件